U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

U.S. permanent implant ... Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the ...

U.S. permanent implant ... Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the ...

(AP) — Nevro Corp. (NVRO) on Tuesday reported a loss ... The maker of an electrical implant that treats leg and back pain posted revenue of $105.5 million in the period, which also topped ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...